Unique ID issued by UMIN | UMIN000025801 |
---|---|
Receipt number | R000029648 |
Scientific Title | A randomized controlled trial comparing Vonoprazan, Amoxicillin, Metronidazole triple therapy and Rabeprazole, Amoxicillin, Metronidazole triple therapy as a second-line eradication of Helicobacter pylori |
Date of disclosure of the study information | 2017/01/24 |
Last modified on | 2020/02/06 13:25:41 |
A randomized controlled trial comparing Vonoprazan, Amoxicillin, Metronidazole triple therapy and Rabeprazole, Amoxicillin, Metronidazole triple therapy as a second-line eradication of Helicobacter pylori
RCT comparing VAM and RAM HP eradication as second-line
A randomized controlled trial comparing Vonoprazan, Amoxicillin, Metronidazole triple therapy and Rabeprazole, Amoxicillin, Metronidazole triple therapy as a second-line eradication of Helicobacter pylori
RCT comparing VAM and RAM HP eradication as second-line
Japan |
Helicobacter pylori infection
Gastroenterology |
Others
NO
To compare the efficacy and safety between Vonoprazan/Amoxicillin/Metronidazole and Rabeprazole/Amoxicillin/Metronidazole 7 day triple therapy for second-line Helicobacter pylori eradication therapy
Safety,Efficacy
Eradication rate assessed by urea breath test more than 8 weeks after treatment
Safety evaluated by side effect questionnaire filled by patients
Interventional
Parallel
Randomized
Individual
Open -no one is blinded
Active
2
Treatment
Medicine |
Vonoprazan 20mg bid
Amoxicillin 750mg bid
Metronidazole 250mg bid
7 days
Rabeprazole 10mg bid
Amoxicillin 750mg bid
Metronidazole 250mg bid
7 days
20 | years-old | <= |
Not applicable |
Male and Female
A patient who failed first-line eradication therapy with Vonoprazan, Amoxicillin and Clarithromycin.
A patient who can do eradication therapy as second time(second-line) in this study.
A patient who was diagnosed for Helicobacter pylori infection and failure of first-line eradication by urea breath test or Helicobacter pylori stool antigen test.
A patient who can perform urea breath test after 8 weeks from treatment completion.
A patient who give a written informed consent.
A patient who has eradication history except triple therapy with Vonoprazan, Amoxicillin and Clarithromycin.
Pregnancy or lactation. Past history of allergy for the drugs used in this study. A patient with brain and spinal cord disease. A patient with infectious mononucleosis. Severe liver dysfunction, severe renal dysfunction, severe heart dysfunction. Patient who is disqualified for the study by physicians.
80
1st name | Shin |
Middle name | |
Last name | Maeda |
Yokohama City University Hospital
Gastroenterology
236-0004
Fukuura3-9, Kanazawa, Yokohama, Kanagawa, Japan
045-261-5656
smaeda@med.yokohama-cu.ac.jp
1st name | Soichiro |
Middle name | |
Last name | Sue |
Yokohama City University Hospital
Gastroenterology
236-0004
Fukuura3-9, Kanazawa, Yokohama, Kanagawa, Japan
045-261-5656
ssue@yokohama-cu.ac.jp
Yokohama City University Hospital
Yokohama City University (Basic research expenditures)
Other
Japan
Yokohama City University Ethics Committee
Fukuura 3-9, Kanazawa-ku, Yokohama city, Kanagawa
045-370-7627
rinri@yokohama-cu.ac.jp
NO
2017 | Year | 01 | Month | 24 | Day |
Unpublished
Open public recruiting
2016 | Year | 12 | Month | 16 | Day |
2017 | Year | 01 | Month | 24 | Day |
2017 | Year | 01 | Month | 23 | Day |
2020 | Year | 02 | Month | 06 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029648